Synthetic oligosaccharides as heparin-mimetics displaying anticoagulant properties.
Heparin and low molecular weight heparins are major clinical anticoagulants and the drugs of choice for the treatment of deep venous thrombosis. The discovery of an antithrombin binding domain in heparin focused interest on understanding the mechanism of heparin's antithrombotic/ anticoagulant activity. Various heparin-mimetic oligosaccharides have been prepared in an effort to replace polydisperse heparin and low molecular weight heparins with a structurally-defined anticoagulant. The goal of attaining a heparin-mimetic with no unwanted side-effects has also provided motivation for these efforts. This article reviews structure-activity relationship (SAR) of structurally-defined heparin-mimetic oligosaccharides.
Avci
Fikri Y
FY
Department of Chemistry, Medicinal and Natural Products Chemistry and Chemical and Biochemical Engineering, University of Iowa, Iowa City, Iowa 52242, USA.
Karst
Nathalie A
NA
Linhardt
Robert J
RJ
D000818:Animals; D000925:Anticoagulants / Q000737:chemistry / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D006493:Heparin / Q000737:chemistry / Q000494:pharmacology; D006801:Humans; D015394:Molecular Structure; D009844:Oligosaccharides / Q000737:chemistry / Q000494:pharmacology; D013329:Structure-Activity Relationship
D000925:Anticoagulants; D009844:Oligosaccharides; D006493:Heparin